Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer.

Schwartz DL, Bankson JA, Lemos R Jr, Lai SY, Thittai AK, He Y, Hostetter G, Demeure MJ, Von Hoff DD, Powis G.

Mol Cancer Ther. 2010 Jul;9(7):2057-67. doi: 10.1158/1535-7163.MCT-09-0768. Epub 2010 Jun 29.

2.

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM.

J Clin Invest. 2010 Mar;120(3):694-705. doi: 10.1172/JCI40283. Epub 2010 Feb 22.

3.

The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects.

Schwartz DL, Powis G, Thitai-Kumar A, He Y, Bankson J, Williams R, Lemos R, Oh J, Volgin A, Soghomonyan S, Nishii R, Alauddin M, Mukhopadhay U, Peng Z, Bornmann W, Gelovani J.

Mol Cancer Ther. 2009 Apr;8(4):947-58. doi: 10.1158/1535-7163.MCT-08-0981.

4.

Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha.

Kim WY, Oh SH, Woo JK, Hong WK, Lee HY.

Cancer Res. 2009 Feb 15;69(4):1624-32. doi: 10.1158/0008-5472.CAN-08-0505. Epub 2009 Jan 27.

5.

Low-field paramagnetic resonance imaging of tumor oxygenation and glycolytic activity in mice.

Matsumoto S, Hyodo F, Subramanian S, Devasahayam N, Munasinghe J, Hyodo E, Gadisetti C, Cook JA, Mitchell JB, Krishna MC.

J Clin Invest. 2008 May;118(5):1965-73. doi: 10.1172/JCI34928.

7.

Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging.

Jackson A, O'Connor JP, Parker GJ, Jayson GC.

Clin Cancer Res. 2007 Jun 15;13(12):3449-59. Review.

9.

Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy.

Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, Hill RP, Koch CJ, Krishna MC, Krohn KA, Lewis JS, Mason RP, Melillo G, Padhani AR, Powis G, Rajendran JG, Reba R, Robinson SP, Semenza GL, Swartz HM, Vaupel P, Yang D, Croft B, Hoffman J, Liu G, Stone H, Sullivan D.

Int J Radiat Biol. 2006 Oct;82(10):699-757. Review.

PMID:
17118889
10.

Characterizing vascular parameters in hypoxic regions: a combined magnetic resonance and optical imaging study of a human prostate cancer model.

Raman V, Artemov D, Pathak AP, Winnard PT Jr, McNutt S, Yudina A, Bogdanov A Jr, Bhujwalla ZM.

Cancer Res. 2006 Oct 15;66(20):9929-36.

11.

Hypoxia signalling in cancer and approaches to enforce tumour regression.

Pouysségur J, Dayan F, Mazure NM.

Nature. 2006 May 25;441(7092):437-43. Review.

PMID:
16724055
12.

Correlation between estimates of tumor perfusion from microbubble contrast-enhanced sonography and dynamic contrast-enhanced magnetic resonance imaging.

Yankeelov TE, Niermann KJ, Huamani J, Kim DW, Quarles CC, Fleischer AC, Hallahan DE, Price RR, Gore JC.

J Ultrasound Med. 2006 Apr;25(4):487-97.

PMID:
16567438
13.

Angiogenesis in life, disease and medicine.

Carmeliet P.

Nature. 2005 Dec 15;438(7070):932-6. Review.

PMID:
16355210
14.

Hypoxia inducible factor-1: a novel target for cancer therapy.

Belozerov VE, Van Meir EG.

Anticancer Drugs. 2005 Oct;16(9):901-9. Review.

PMID:
16162966
15.

Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity.

Moeller BJ, Dreher MR, Rabbani ZN, Schroeder T, Cao Y, Li CY, Dewhirst MW.

Cancer Cell. 2005 Aug;8(2):99-110.

16.

Therapeutic targeting of the tumor microenvironment.

Joyce JA.

Cancer Cell. 2005 Jun;7(6):513-20. No abstract available.

17.

Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1.

Williams KJ, Telfer BA, Xenaki D, Sheridan MR, Desbaillets I, Peters HJ, Honess D, Harris AL, Dachs GU, van der Kogel A, Stratford IJ.

Radiother Oncol. 2005 Apr;75(1):89-98. Epub 2005 Apr 18.

PMID:
15878106
18.

Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells.

Wang V, Davis DA, Haque M, Huang LE, Yarchoan R.

Cancer Res. 2005 Apr 15;65(8):3299-306.

19.

Synthesis and characterization of poly(L-glutamic acid) gadolinium chelate: a new biodegradable MRI contrast agent.

Wen X, Jackson EF, Price RE, Kim EE, Wu Q, Wallace S, Charnsangavej C, Gelovani JG, Li C.

Bioconjug Chem. 2004 Nov-Dec;15(6):1408-15.

PMID:
15546209
20.

Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis.

Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber HP, Ferrara N, Johnson RS.

Cancer Cell. 2004 Nov;6(5):485-95.

Supplemental Content

Support Center